Page last updated: 2024-12-05

benoxinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benoxinate: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxybuprocaine : A benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester "caine") used especially in ophthalmology and otolaryngology. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4633
CHEMBL ID1200
CHEBI ID309594
SCHEMBL ID25087
MeSH IDM0046757

Synonyms (88)

Synonym
BRD-K04185004-003-03-6
4-amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester
PRESTWICK2_000057
brn 2288926
oxybuprocainum [inn-latin]
oxibuprocaina [inn-spanish]
novesinol
oxbarukain
oxybuprocaine [inn:ban]
4-amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [german]
cas-5987-82-6
NCGC00016667-01
PRESTWICK3_000057
MLS001332643
MLS001332644
smr000857098
benoxinate
butoxyaminobenzoyldiethylaminoethanol
oxybuprocaine
s 749
benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7ci,8ci,9ci)
prescaina
dorsacain
conjucain
oxibuprocainum
99-43-4
benoxil
4-amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester
oxybucaine
2-(diethylamino)ethyl 4-amino-3-butoxybenzoate
benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester
2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate
4-amino-3-butoxybenzoic acid 2-diethylaminoethyl ester
3-butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester
4-amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid
2-diethylaminoethyl 4-amino-3-butoxybenzoate
oxibuprokain
3-butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester
4-amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester
DB00892
oxyriprocaine
BSPBIO_000213
PRESTWICK1_000057
SPBIO_002134
PRESTWICK0_000057
BPBIO1_000235
NCGC00016667-02
monofree oxybuprocaine
CHEMBL1200
2-(4-amino-3-butoxybenzoyl)oxyethyl-diethylazanium chloride
D08319
oxybuprocaine (inn)
monofree oxybuprocaine (tn)
FT-0659855
oxybuprocainum
oxibuprocaina
chebi:309594 ,
AKOS005457803
BBL003343
STK520615
HMS2235J23
axq0jym303 ,
unii-axq0jym303
EPITOPE ID:122669
gtpl7123
HMS3369H13
minims oxybuprocaine
oxybuprocaine [inn]
oxybuprocaine [who-dd]
benoxinate [vandf]
benoxinate [mi]
SCHEMBL25087
DTXSID7048530
CMHHMUWAYWTMGS-UHFFFAOYSA-N
HMS3604F05
4675B
NCGC00016667-05
2-(diethylamino)ethyl 4-amino-3-butoxy-benzoate
BS-18026
bdbm50225499
Q1530958
benoxinate;conjucain; dorsacain; novesinol; oxybucaine
mfcd00242863
D83117
HY-B1288A
EN300-17989125
CS-0013333
2-(diethylamino)ethyl4-amino-3-butoxybenzoate

Research Excerpts

Overview

Benoxinate is a local anaesthetic used for ophthalmic applications.

ExcerptReferenceRelevance
"Benoxinate is a local anaesthetic used for ophthalmic applications. "( Development and validation of a stability-indicating high performance liquid chromatographic assay for benoxinate.
Chorny, M; Gruzman, B; Levy, D; Lichaa, C; Livshits, O; Lomnicky, Y; Schumacher, I, 2003
)
1.98

Toxicity

ExcerptReferenceRelevance
" Specular microscopy performed at 30 days postoperatively showed a significantly greater loss of endothelial cells with the use of VisThesia, suggesting that the 1% lidocaine concentration used in VisThesia may be toxic to corneal endothelial cells."( Safety and efficacy of two ocular anesthetic methods for phacoemulsification: topical anesthesia and viscoanesthesia (VisThesia).
Herasymyuk, O; Ouled-Moussa, R; Perone, JM; Popovici, A; Reynders, S,
)
0.13
" To this end we assessed the incidence of patients' preoperative anxiety, perioperative adverse events and patients' and surgeons' satisfaction."( [Simplified topical anesthesia protocol for ambulatory cataract surgery: safety and patient and surgeon satisfaction].
Angioi, K; Batta, B; Fuchs-Buder, T; Tréchot, F, 2014
)
0.4
" An anesthesiologist and nurse anesthetist were present in the area and could intervene in case of an adverse event."( [Simplified topical anesthesia protocol for ambulatory cataract surgery: safety and patient and surgeon satisfaction].
Angioi, K; Batta, B; Fuchs-Buder, T; Tréchot, F, 2014
)
0.4
" Twenty-three adverse events occurred of which 16 required interventions by the anaesthesiologist or surgeon: 5 supplemental local or regional anaesthesia, 6 iv-analgesia, 5 management of hypertension."( [Simplified topical anesthesia protocol for ambulatory cataract surgery: safety and patient and surgeon satisfaction].
Angioi, K; Batta, B; Fuchs-Buder, T; Tréchot, F, 2014
)
0.4
" Our results suggest that OBPC has a dose- and time-dependent cytotoxicity to HCEP cells by inducing cell cycle arrest and cell apoptosis via a death receptor-mediated mitochondria-dependent proapoptotic pathway, and this novel finding provides new insights into the acute cytotoxicity and its toxic mechanisms of OBPC on HCEP cells."( The cytotoxic effect of oxybuprocaine on human corneal epithelial cells by inducing cell cycle arrest and mitochondria-dependent apoptosis.
Fan, TJ; Fan, WY; Wang, DP; Wen, Q, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
"To assess safety of topical anesthesia for transpupillary silicone oil removal in combination with cataract surgery."( Topical anesthesia for transpupillary silicone oil removal combined with cataract surgery.
Hugger, P; Jonas, JB; Sauder, G, 2005
)
0.33
"The clinical interventional study included 37 consecutive patients having transpupillary silicone oil removal combined with cataract surgery."( Topical anesthesia for transpupillary silicone oil removal combined with cataract surgery.
Hugger, P; Jonas, JB; Sauder, G, 2005
)
0.33

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" After rats were injected intrathecally with proxymetacaine, oxybuprocaine, bupivacaine, and lidocane, dose-response curves were constructed."( Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats.
Chen, YC; Chen, YW; Chu, CC; Hung, CH; Wang, JJ, 2009
)
0.35
"To compare a surgically adjusted dose of strabismus surgery using topical anesthesia in cooperative patients with dosage guidelines adapted to the surgeon's personal technique using sub-Tenon's anesthesia."( Surgery for esotropia under topical anesthesia.
Ogallar, C; Rodríguez, JM; Tejedor, J, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
local anaestheticAny member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
topical anaestheticA local anesthetic that is used to numb the surface of a body part.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
substituted aniline
amino acid esterAny carboxylic ester derivative of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Oxybuprocaine Action Pathway3111

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
IDH1Homo sapiens (human)Potency3.66260.005210.865235.4813AID686970
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency6.30960.00207.533739.8107AID891
gemininHomo sapiens (human)Potency25.92900.004611.374133.4983AID624296
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.15850.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)309.10000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1061889Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID250135Inhibition of compound against MES-SA/DX5 cell line was determined using P-glycoprotein assay2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (188)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (23.40)18.7374
1990's38 (20.21)18.2507
2000's52 (27.66)29.6817
2010's39 (20.74)24.3611
2020's15 (7.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.51 (24.57)
Research Supply Index5.51 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index72.16 (26.88)
Search Engine Supply Index2.16 (0.95)

This Compound (43.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials49 (24.75%)5.53%
Reviews2 (1.01%)6.00%
Case Studies20 (10.10%)4.05%
Observational1 (0.51%)0.25%
Other126 (63.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Dexmedetomidine With or Without Pregabalin Premedication for Conscious Sedation During Cataract Surgery Under Topical Anesthesia. A Randomized Double-blind Placebo-controlled Trial. [NCT03735368]Phase 260 participants (Actual)Interventional2018-12-10Completed
Hemodynamic Response Of Premature Brain To Pain During Retinopathy Of Prematurity Screening: A Randomized Controlled Trial [NCT05666362]40 participants (Anticipated)Interventional2022-03-20Recruiting
A Prospective, Observer-blind, Randomized Clinical Trial to Investigate and Compare the Clinical Efficacy of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia for Clinical Practice in Pediatric Population [NCT05926258]Phase 374 participants (Anticipated)Interventional2024-02-29Not yet recruiting
Nalbuphine/Dexmedetomidine Versus Nalbuphine/Propofol Conscious Sedation for Cataract Extraction Under Topical Anaesthesia: A Double-Blind Randomized Trial [NCT03933280]Phase 2100 participants (Actual)Interventional2019-07-01Completed
VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia [NCT02528123]187 participants (Anticipated)Interventional2016-04-30Active, not recruiting
Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa : Study of a Handheld in Vivo Confocal Microscope and of a Fluorescent in Vivo Confocal Microscope [NCT02386774]130 participants (Anticipated)Interventional2016-03-21Recruiting
Preservative-free Topical Anesthetics for the Management of Postoperative Pain Following Photorefractive Keratectomy [NCT05733741]Phase 470 participants (Actual)Interventional2023-01-30Completed
Optimization of Sampling for Molecular Microbial Research on Ocular Surface Samples and Building a Framework for Comparing Current Sequencing Results Using Different Extraction Protocols. [NCT04193774]24 participants (Actual)Interventional2019-08-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]